MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-18-0000247
Agio Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹287.95 Cr
▲ 29% YoY
Net profit · FY 2025
₹31.33 Cr
Net margin 10.9%
EBITDA · FY 2025
₹75.26 Cr
EBITDA margin 26.1%
Authorised capital
₹6 Cr
Registered with MCA
Paid-up capital
₹5.18 Cr
Issued & subscribed
Open charges
₹75.02 Cr
Satisfied ₹205.08 Cr
Company age
34 yrs
Est. 1992
Employees · EPFO
343
Provident fund records
About Agio Pharmaceuticals Limited
Data last updated:
Agio Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 January 1992 and has been in existence for over 34 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1992PLC065031. Its GSTIN is 27AABCA8426A1Z3 (Maharashtra). The company holds 4 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹6 Cr and a paid-up capital of ₹5.18 Cr. It is led by directors including Madhusudan Govindprasad Ruia (Managing Director) and Mahendra Kumar Kumawat (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A – 38 Nandjyot Industrial Estate Kurla Andheri Road Safed Pool, Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2025, the company reported a revenue of ₹287.95 Cr, a growth of 29% compared to the previous year. For the same year it recorded a net profit of ₹31.33 Cr (net margin 10.9%) and EBITDA of ₹75.26 Cr (EBITDA margin 26.1%). Revenue has grown at a compounded annual rate (CAGR) of 38% over three years and 19% over five years.
The company has about 343 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Agio Pharmaceuticals. As per MCA filings, the company has open charges of ₹75.02 Cr and satisfied charges of ₹205.08 Cr on record. Court records list 25 cases involving the company, including 4 filed by the company and 21 filed against it; 10 cases are pending. The company has 11 deals on record (7 secondary share transfers, 4 funding rounds), with disclosed funding of ₹17.67 Cr; the latest was in November 2021. Its 7 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Biomatrix Healthcare Private Limited with revenue of ₹295.64 Cr. The company has 24 MSME Form 1 returns on record between 2018 and 2024, listing 4,711 overdue payments to 148 micro and small suppliers.
Agio Pharmaceuticals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0000247). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website agio-pharma.com.
Company details
CIN U24239MH1992PLC065031
Registration Number 065031
Incorporation Date 24 January 1992
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-18-0000247
CIN history
Agio Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239MH1992PTC065031. The current CIN is U24239MH1992PLC065031, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH1992PLC065031 | Current |
| U24239MH1992PTC065031 | Previous |
Key People
Madhusudan Govindprasad Ruia Managing Director Mahendra Kumar Kumawat Whole-Time Director Raghav Sanjay Ruia Whole-Time Director Recognitions & Rankings of Agio Pharmaceuticals
Contact details
Agio Pharmaceuticals Limited's registered office is in Mumbai, Maharashtra. Its website is agio-pharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 38 Nandjyot Industrial Estate Kurla Andheri Road Safed Pool, Mumbai, Maharashtra, India – 400072
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Agio Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Agio Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Agio Pharmaceuticals operates one associated brand: Agio Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products for human and animal healthcare operations in India. | agio-pharma.com |
Business activity
The main business activity of Agio Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Agio Pharmaceuticals Limited, buy the company report.
Financials of Agio Pharmaceuticals Limited
FY 2025 filings availableAgio Pharmaceuticals Limited reported revenue of ₹287.95 Cr (up 29% YoY) for FY 2025.
Revenue · FY 2025
₹287.95 Cr ▲ 29%
Net profit · FY 2025
₹31.33 Cr margin 10.9%
EBITDA · FY 2025
₹75.26 Cr margin 26.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 29%
3 years · compounded
▲ 38%
5 years · compounded
▲ 19%
EBITDA CAGR growth
1 year
▲ 115%
3 years · compounded
▲ 90%
5 years · compounded
▲ 33%
Revenue has grown at a compounded annual rate (CAGR) of 19% over five years, including 29% growth in the latest year. EBITDA rose 115% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹75.26 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹31.33 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 26.1% | ||||
| Net Profit Margin | 10.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Agio Pharmaceuticals Limited, buy the company report.
Board of directors of Agio Pharmaceuticals Limited
Agio Pharmaceuticals has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahendra Kumar Kumawat | Whole-Time Director | 09 Sep 2020 | 6 Years 1 Months | Current |
| Raghav Sanjay Ruia Also directs: Bhakti Enterprises Limited | Whole-Time Director | 04 Oct 2019 | 7 Years 0 Months | Current |
| Madhusudan Govindprasad Ruia | Managing Director | 24 Jan 1992 | 34 Years 8 Months | Current |
Peer comparison
Agio Pharmaceuticals Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Biomatrix Healthcare Private Limited | ₹295.64 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Globela Pharma Private Limited | ₹295.59 Cr (FY 2025) | 13.0% | Surat, Gujarat, India | |||
| Ravenbhel Health Care Private Limited | ₹290.95 Cr (FY 2025) | 16.0% | Jammu, Jammu and Kashmir, India | |||
| Agio Pharmaceuticals Limitedthis company | ₹287.95 Cr (FY 2025) | ₹31.33 Cr | 10.9% | 29.0% | 343 | Mumbai, Maharashtra, India |
| Gracure Pharmaceuticals Limited | ₹287.44 Cr (FY 2025) | 27.0% | New Delhi, Delhi, India | |||
| Pinnacle Life Science Private Limited | ₹286.72 Cr (FY 2023) | -2.0% | Baddi, Himachal Pradesh, India | |||
| Sava Healthcare Limited | ₹284.97 Cr (FY 2025) | 14.0% | Wadhwan, Gujarat, India | |||
| Med Manor Organics Private Limited | ₹284.93 Cr (FY 2025) | 5.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Agio Pharmaceuticals Limited, buy the company report.
Auditor
Agio Pharmaceuticals Limited is audited by Kanodia Sanyal & Associates. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Kanodia Sanyal & Associates. | FY 2023 | 008396N |
Shareholding
The shareholding of Agio Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2022, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Agio Pharmaceuticals Limited, buy the company report.
Charges & borrowings
Open charges
₹75.02 Cr
Satisfied charges
₹205.08 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 13 Oct 2025 | 101191467 | Hdfc Bank Limited | ₹43 Lakh | Open | |
| 28 Nov 2024 | 101019912 | Others | ₹58 Lakh | Open | |
| 18 Mar 2024 | 100897901 | Sbicap Trustee Company Limited | ₹65.69 Cr | Open | |
| 10 Nov 2023 | 100815889 | Others | ₹51 Lakh | Open | |
| 21 Jul 2023 | 100754235 | Axis Bank Limited | ₹80 Lakh | Open |
To see the full charge records of Agio Pharmaceuticals Limited, buy the company report.
Total charge records: 25 View all charges
Deals & funding
Agio Pharmaceuticals Limited has 11 deals on record (7 secondary share transfers, 4 funding rounds), with disclosed funding of ₹17.67 Cr; the latest was in November 2021.
Total deals
11
Secondary share transfers
7
Funding rounds
4
Disclosed funding
₹17.67 Cr
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2021 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: Sanjay Ruia (HUF) |
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: Shree Madhu Realtors Private Limited Seller: Emfor International Limited |
| Mar 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: Shree Madhu Realtors Private Limited Seller: an individual |
| Dec 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Agio Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Agio Pharmaceuticals Limited has 25 court cases on record: 4 filed by Agio Pharmaceuticals, 21 filed against it. 10 cases are pending and 15 are disposed.
Total cases
25
Filed by the company
4
Filed against the company
21
Pending
10
Disposed
15
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 18 | 17 | 8 |
| High courts | 7 | 4 | 2 |
Cases on record (5 of 25)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Kishore Pharma Products Pvt. Ltd., | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Kishore Pharma Products Pvt. Ltd., | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMONS CASES SS) | Filed against the company by Ms Ahlcon Parenterals India Ltd. | Disposed |
| District court, Maharashtra Industrial and Lab, Maharashtra | Court case (Condn of Delay ULP) | Filed against the company by an individual | Pending |
| District court, Maharashtra Industrial and Lab, Maharashtra | Court case (Condn of Delay ULP) | Filed against the company by an individual | Pending |
To see the full case history of Agio Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Agio Pharmaceuticals Limited was last rated by Care on 03 Feb 2023.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 03 Feb 2023 |
To see the full credit ratings and regulatory alerts of Agio Pharmaceuticals Limited, buy the company report.
MSME payment delays
Agio Pharmaceuticals Limited has 24 MSME Form 1 returns on record between 2018 and 2024, listing 4,711 overdue payments to 148 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 148)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Amr Print & Pack | |||
| Omkar Traders | |||
| Amartara Private Limited | |||
| Hym Brothers |
To see the full MSME payment records of Agio Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Agio Pharmaceuticals Limited has a workforce of 343 employees on its EPFO records as of Apr 04, 2024, across 2 active EPFO establishments.
Employee count
343
Active EPFO establishments
2
Employee growth
5.21%
GST
Agio Pharmaceuticals has 4 GST registrations: 1 active and 3 cancelled or inactive.
Total GSTINs
4
Active
1
Cancelled / inactive
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCA8426A1Z3 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Agio Pharmaceuticals Limited, buy the company report.
Recent activity
Agio Pharmaceuticals Limited has 7 board changes on record since 1992: 3 appointments and 4 cessations. The latest: Sunil Rajaram Rane ceased to be Whole-Time Director on 17 Sep 2020.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.43 Cr with Charge ID 101191467 was registered on 13 Oct 2025.
AGM
Agio Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Agio Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge with Others amounted to Rs. 0.58 Cr with Charge ID 101019912 was registered on 28 Nov 2024.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 65.69 Cr registered on 18 Mar 2024 with Charge ID 100897901 was modified on 24 Jul 2024.
Charges
A charge with Others of Rs. 0.84 Cr registered on 23 Mar 2011 with Charge ID 10286381 was modified on 29 May 2024.
Charges
A charge registered on 29 Nov 2021 via Charge ID 100513265 with Others was fully satisfied on 10 May 2024.
Charges
A charge registered on 30 Dec 2020 via Charge ID 100402379 with Others was fully satisfied on 10 May 2024.
Charges
A charge registered on 24 Jun 2010 via Charge ID 10235351 with Others was fully satisfied on 10 May 2024.
Charges
A charge with Sbicap Trustee Company Limited amounted to Rs. 65.69 Cr with Charge ID 100897901 was registered on 18 Mar 2024.
Charges
A charge with Others amounted to Rs. 0.51 Cr with Charge ID 100815889 was registered on 10 Nov 2023.
Charges
A charge with Axis Bank Limited amounted to Rs. 0.80 Cr with Charge ID 100754235 was registered on 21 Jul 2023.
52 earlier events are in the company report.
Frequently asked questions
Agio Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 January 1992 (34+ years old) and is registered under CIN U24239MH1992PLC065031.
Agio Pharmaceuticals has 3 current directors:
- Madhusudan Govindprasad Ruia - Managing Director
- Mahendra Kumar Kumawat - Whole-Time Director
- Raghav Sanjay Ruia - Whole-Time Director
The latest financial statements of Agio Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Agio Pharmaceuticals is 27AABCA8426A1Z3, registered in Maharashtra. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.
The CIN (Corporate Identification Number) of Agio Pharmaceuticals is U24239MH1992PLC065031. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Agio Pharmaceuticals has 25 court cases on record: 4 filed by the company and 21 filed against it. 10 are pending. Most are in the district courts.
Agio Pharmaceuticals was incorporated on 24 January 1992, making it 34+ years old. It is registered with the Registrar of Companies, Mumbai.
Agio Pharmaceuticals has 11 deals on record (7 secondary share transfers, 4 funding rounds), with disclosed funding of ₹17.67 Cr; the latest was in November 2021.
The peers of Agio Pharmaceuticals by revenue are Biomatrix Healthcare Private Limited, Globela Pharma Private Limited, Ravenbhel Health Care Private Limited, Gracure Pharmaceuticals Limited, Pinnacle Life Science Private Limited and 2 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sunil Rajaram Rane ceased to be Whole-Time Director on 17 Sep 2020. Mahendra Kumar Kumawat was appointed as Whole-Time Director on 09 Sep 2020. Pankaj Nandkishor Chandak ceased to be Whole-Time Director on 09 Oct 2019. Agio Pharmaceuticals has 7 board changes on record in total.
Yes, Agio Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-18-0000247).
Agio Pharmaceuticals has 24 MSME Form 1 returns on record between 2018 and 2024, listing 4,711 overdue payments to 148 micro and small suppliers. The latest return was filed on 26 Apr 2024.